N'-(4-TRIFLUOROMETHYLBENZYLIDENE)-1-PHENYL-BETA-CARBOLINE-3-CARBOHYDRAZIDE


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	UHUNBKQMVNWSPZ-MNDYBZJGSA-N
Smiles	FC(F)(F)c1ccc(\C=N/NC(=O)c2cc3c4ccccc4[nH]c3c(n2)c5ccccc5)cc1
InChI	InChI=1S/C26H17F3N4O/c27-26(28,29)18-12-10-16(11-13-18)15-30-33-25(34)22-14-20-19-8-4-5-9-21(19)31-24(20)23(32-22)17-6-2-1-3-7-17/h1-15,31H,(H,33,34)/b30-15-

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C26H17F3N4O
Molecular Weight	458.43
AlogP	6.34
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	5.0
Polar Surface Area	70.14
Molecular species	NEUTRAL
Aromatic Rings	5.0
Heavy Atoms	34.0

Assay Description	Organism	Bioactivity
Herbicidal activity against Echinochloa crus-galli (barnyard grass)	Echinochloa crus-galli	14250.0 nM
Herbicidal activity against Brassica rapa subsp. oleifera	Brassica rapa subsp. oleifera	14250.0 nM
Herbicidal activity against Echinochloa crus-galli (barnyard grass) assessed as growth inhibition at 10 ug/ml	Echinochloa crus-galli	27.94 %
Herbicidal activity against Echinochloa crus-galli (barnyard grass) assessed as growth inhibition at 100 ug/ml	Echinochloa crus-galli	60.32 %
Herbicidal activity against Brassica rapa subsp. oleifera assessed as growth inhibition at 10 ug/ml	Brassica rapa subsp. oleifera	57.85 %
Herbicidal activity against Brassica rapa subsp. oleifera assessed as growth inhibition at 100 ug/ml	Brassica rapa subsp. oleifera	100.0 %

Cross References

Resources	Reference
ChEMBL	CHEMBL2272724
PubChem	76330714

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).